Pune: Gennova Biopharmaceuticals Ltd., a subsidiary of Emcure Pharmaceuticals Ltd., has announced significant progress in developing India’s first AI-enhanced self-amplifying mRNA (saRNA) vaccine targeting the highly fatal Nipah virus. The initiative has received $13.38 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) as part of a broader effort to strengthen pandemic preparedness.
As part of this initiative, Gennova is collaborating with the U.S.-based Houston Methodist Research Institute (HMRI), another CEPI partner, to integrate artificial intelligence (AI) technology. This AI-driven approach will optimize viral proteins that can trigger an effective immune response, improving vaccine efficacy and accelerating research efforts.
Addressing a Global Health Threat
Nipah virus, classified under the Paramyxovirus family, is among the deadliest viruses affecting humans, with outbreaks primarily reported in South and Southeast Asia. However, its fruit-bat carrier species are found across large global regions, putting over two billion people at potential risk.
While no vaccines or specific treatments are currently available for Nipah virus infections, CEPI has been leading the global effort to develop a solution, investing over $100 million into Nipah vaccine research.
“With no approved vaccines or targeted therapeutics against Nipah, CEPI is committed to developing protective measures against this deadly virus. Our collaboration with Gennova not only enhances the capabilities of saRNA vaccines for Nipah but also strengthens the broader RNA-based response to future pandemic threats within 100 days of outbreak identification,” said Dr. Kent Kester, Executive Director of Vaccine Research & Development at CEPI.
saRNA: A Breakthrough in Vaccine Technology
Traditional mRNA vaccines instruct the body’s cells to produce antigenic proteins, triggering an immune response. Self-amplifying RNA (saRNA) vaccines further enhance this process by replicating mRNA within the body, enabling a stronger immune response at lower doses compared to standard mRNA vaccines.
In August 2023, CEPI initially granted $3.6 million to Gennova’s saRNA platform, supporting the development of vaccine candidates for unknown pathogens—also referred to as Disease X threats. The funding is part of a larger CEPI initiative to develop next-generation RNA vaccines offering faster response times, multivalency, improved stability, and cost-effectiveness.
A Commitment to Equitable Access
Dr. Sanjay Singh, CEO of Gennova Biopharmaceuticals, underscored the significance of the collaboration: “By harnessing our cutting-edge saRNA platform, we aim to create a revolutionary vaccine against Nipah. This collaboration not only advances vaccine innovation but also ensures fair and equitable access, reinforcing global health security.”
As part of its agreement with CEPI, Gennova has pledged to ensure that its vaccines are first made available to at-risk populations at an affordable price. Additionally, the collaboration includes provisions for technology transfer, ensuring that Gennova’s advancements contribute to future pandemic preparedness and vaccine development worldwide.
